Expanding CD38-targeting triplets for relapsed or refractory multiple myeloma
Mené dans 16 pays sur 302 patients atteints d'un myélome multiple récidivant, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de l'isatuximab à un traitement combinant carfilzomib et dexaméthasone
In the rapidly evolving treatment landscape for multiple myeloma, the optimal choiceand sequencing of drugs are challenging. At the time of clinical relapse, a number of factors related to the host and thedisease ultimately affects treatment selection. However, the depth and duration of response, exposure to previous drugs, and refractorinessto one or more classes of agents, particularly in the last treatment line, are crucial for the selection of the best sequence.
The Lancet 2021